128 related articles for article (PubMed ID: 16771170)
21. Diagnostic and prognostic information obtained on fine-needle aspirates of primary neuroblastic tumors: Proposal for a cytology prognostic score.
Klijanienko J; Couturier J; Brisse H; Pierron G; Fréneaux P; Berger F; Maciorowski Z; Sastre-Garau X; Michon J; Schleiermacher G
Cancer Cytopathol; 2011 Dec; 119(6):411-23. PubMed ID: 21774092
[TBL] [Abstract][Full Text] [Related]
22. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
[TBL] [Abstract][Full Text] [Related]
23. Competitive polymerase chain reaction for the determination of N-myc amplification in neuroblastoma: report of clinical cases.
Hasan Z; Inoue A; Ikeda H; Kamii Y; Obana K; Yokomori K; Tsuchida Y; Hemmi H; Shimatake H
Eur J Pediatr Surg; 1999 Jun; 9(3):138-41. PubMed ID: 10427487
[TBL] [Abstract][Full Text] [Related]
24. Rapid detection of MYCN gene amplification in neuroblastomas using the polymerase chain reaction.
Crabbe DC; Peters J; Seeger RC
Diagn Mol Pathol; 1992 Dec; 1(4):229-34. PubMed ID: 1342970
[TBL] [Abstract][Full Text] [Related]
25. Evolution of unbalanced gain of distal chromosome 2p in neuroblastoma.
Stallings RL; Carty P; McArdle L; Mullarkey M; McDermott M; O'Meara A; Ryan E; Catchpoole D; Breatnach F
Cytogenet Genome Res; 2004; 106(1):49-54. PubMed ID: 15218241
[TBL] [Abstract][Full Text] [Related]
26. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
[TBL] [Abstract][Full Text] [Related]
27. Centrosome amplification is correlated with ploidy divergence, but not with MYCN amplification, in neuroblastoma tumors.
Fukushi D; Watanabe N; Kasai F; Haruta M; Kikuchi A; Kikuta A; Kato K; Nakadate H; Tsunematsu Y; Kaneko Y
Cancer Genet Cytogenet; 2009 Jan; 188(1):32-41. PubMed ID: 19061778
[TBL] [Abstract][Full Text] [Related]
28. Podoplanin lymphatic density and invasion correlate with adverse clinicopathologic and biological factors and survival in neuroblastomas.
Ramani P; Somerville MS; May MT
Am J Surg Pathol; 2012 Jun; 36(6):908-15. PubMed ID: 22588067
[TBL] [Abstract][Full Text] [Related]
29. Detection of N-myc oncogene expression in human neuroblastoma by in situ hybridization and blot analysis: relationship to clinical outcome.
Grady-Leopardi EF; Schwab M; Ablin AR; Rosenau W
Cancer Res; 1986 Jun; 46(6):3196-9. PubMed ID: 2421891
[TBL] [Abstract][Full Text] [Related]
30. Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas.
Ambros PF; Ambros IM; Kerbl R; Luegmayr A; Rumpler S; Ladenstein R; Amann G; Kovar H; Horcher E; De Bernardi B; Michon J; Gadner H
Med Pediatr Oncol; 2001 Jan; 36(1):1-4. PubMed ID: 11464855
[TBL] [Abstract][Full Text] [Related]
31. Chromosome findings and prognosis in 15 patients with neuroblastoma found by VMA mass screening.
Hayashi Y; Inaba T; Hanada R; Yamamoto K
J Pediatr; 1988 Apr; 112(4):567-71. PubMed ID: 3351679
[TBL] [Abstract][Full Text] [Related]
32. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
33. Chromosome bands 1p35-36 contain two distinct neuroblastoma tumor suppressor loci, one of which is imprinted.
Caron H; Spieker N; Godfried M; Veenstra M; van Sluis P; de Kraker J; Voûte P; Versteeg R
Genes Chromosomes Cancer; 2001 Feb; 30(2):168-74. PubMed ID: 11135433
[TBL] [Abstract][Full Text] [Related]
34. Amplification of N-myc oncogene in stage II and IVS neuroblastomas may be a prognostic indicator.
Nakagawara A; Ikeda K; Tsuda T; Higashi K; Okabe T
J Pediatr Surg; 1987 May; 22(5):415-8. PubMed ID: 3585663
[TBL] [Abstract][Full Text] [Related]
35. Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors.
Veschi V; Petroni M; Bartolazzi A; Altavista P; Dominici C; Capalbo C; Boldrini R; Castellano A; McDowell HP; Pizer B; Frati L; Screpanti I; Gulino A; Giannini G
Cell Death Dis; 2014 Mar; 5(3):e1100. PubMed ID: 24603328
[TBL] [Abstract][Full Text] [Related]
36. INSM1 Expression in Peripheral Neuroblastic Tumors and Other Embryonal Neoplasms.
Wang H; Krishnan C; Charville GW
Pediatr Dev Pathol; 2019 Oct; 22(5):440-448. PubMed ID: 30975032
[TBL] [Abstract][Full Text] [Related]
37. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization.
Vandesompele J; Van Roy N; Van Gele M; Laureys G; Ambros P; Heimann P; Devalck C; Schuuring E; Brock P; Otten J; Gyselinck J; De Paepe A; Speleman F
Genes Chromosomes Cancer; 1998 Oct; 23(2):141-52. PubMed ID: 9739017
[TBL] [Abstract][Full Text] [Related]
38. Detection of N-myc amplification in neuroblastomas using Southern blotting on fine needle aspirates.
Barroca H; Carvalho JL; da Costa MJ; Cirnes L; Seruca R; Schmitt FC
Acta Cytol; 2001; 45(2):169-72. PubMed ID: 11284301
[TBL] [Abstract][Full Text] [Related]
39. N-myc gene amplification in neuroblastoma: a clinical approach using ultrasound guided cutting needle biopsies collected at diagnosis.
Hedborg F; Lindgren PG; Johansson I; Kogner P; Samuelsson BO; Bekassy AN; Olsen L; Kreuger A; Påhlman S
Med Pediatr Oncol; 1992; 20(4):292-300. PubMed ID: 1608350
[TBL] [Abstract][Full Text] [Related]
40. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
